IKK phosphorylates RelB to modulate its promoter specificity and promote fibroblast migration downstream of TNF receptors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 41, 2014, Pages 14794-14799

  Authier, Hélène ^f   Billot, Katy ^a,b,c   Derudder, Emmanuel ^d   Bordereaux, Didier ^a,b,c   Rivière, Pierre ^a,b,c   Rodrigues Ferreira, Sylvie ^a   Nahmias, Clara ^a   Baud, Véronique ^a,b,c   Karin, Michael ^e  

^a INSERM   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Metalloproteinase; NF kappab; Posttranslational modification; TNFalpha

Indexed keywords

I KAPPA B; I KAPPA B KINASE; NF-KAPPAB INHIBITOR ALPHA; PHOSPHOSERINE; STROMELYSIN; TRANSCRIPTION FACTOR RELB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL; CELL MOTION; CELL NUCLEUS; CYTOLOGY; DRUG EFFECTS; FIBROBLAST; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; MOUSE; PHOSPHORYLATION; PROMOTER REGION;

ANIMALS; CELL MOVEMENT; CELL NUCLEUS; FIBROBLASTS; HEK293 CELLS; HUMANS; I-KAPPA B KINASE; I-KAPPA B PROTEINS; MATRIX METALLOPROTEINASE 3; MICE; PHOSPHORYLATION; PHOSPHOSERINE; PROMOTER REGIONS, GENETIC; RECEPTORS, TUMOR NECROSIS FACTOR; TRANSCRIPTION FACTOR RELB; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84907937912     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1410124111     Document Type: Article

References (40)

1. Oeckinghaus A, Ghosh S (2009) The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 1(4):a000034.
2. Li Q, Verma IM (2002) NF-kappaB regulation in the immune system. Nat Rev Immunol 2(10):725-734.
3. Baldwin AS (2012) Regulation of cell death and autophagy by IKK and NF-κB: Critical mechanisms in immune function and cancer. Immunol Rev 246(1):327-345.
4. Naugler WE, Karin M (2008) NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 18(1):19-26.
5. Hinz M, Arslan SC, Scheidereit C (2012) It takes two to tango: IκBs, the multifunctional partners of NF-κB. Immunol Rev 246(1):59-76.
6. Natoli G (2012) NF-κB and chromatin: Ten years on the path from basic mechanisms to candidate drugs. Immunol Rev 246(1):183-192.
7. Siggers T, et al. (2012) Principles of dimer-specific gene regulation revealed by a comprehensive characterization of NF-κB family DNA binding. Nat Immunol 13(1):95-102.
8. Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9(5):361-371.
9. Dobrzanski P, Ryseck RP, Bravo R (1995) Specific inhibition of RelB/p52 transcriptional activity by the C-terminal domain of p100. Oncogene 10(5):1003-1007.
10. Baud V, Derudder E (2011) Control of NF-κB activity by proteolysis. Curr Top Microbiol Immunol 349:97-114.
11. Yilmaz ZB, Weih DS, Sivakumar V, Weih F (2003) RelB is required for Peyer's patch development: Differential regulation of p52-RelB by lymphotoxin and TNF. EMBO J 22(1):121-130.
12. Derudder E, et al. (2003) RelB/p50 dimers are differentially regulated by tumor necrosis factor-alpha and lymphotoxin-beta receptor activation: Critical roles for p100. J Biol Chem 278(26):23278-23284.
13. Basak S, et al. (2007) A fourth IkappaB protein within the NF-kappaB signaling module. Cell 128(2):369-381.
14. Jacque E, Tchenio T, Piton G, Romeo PH, Baud V (2005) RelA repression of RelB activity induces selective gene activation downstream of TNF receptors. Proc Natl Acad Sci USA 102(41):14635-14640.
15. Madge LA, May MJ (2010) Classical NF-kappaB activation negatively regulates noncanonical NF-kappaB-dependent CXCL12 expression. J Biol Chem 285(49):38069-38077.
16. Fusco AJ, et al. (2008) Stabilization of RelB requires multidomain interactions with p100/p52. J Biol Chem 283(18):12324-12332.
17. Weih F, et al. (1995) Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell 80(2):331-340.
18. Olashaw NE (1996) Inducible activation of RelB in fibroblasts. J Biol Chem 271(48): 30307-30310.
19. Chen L, Meng Q, Kao W, Xia Y (2011) IκB kinase β regulates epithelium migration during corneal wound healing. PLoS ONE 6(1):e16132.
20. Häcker H, Karin M (2006) Regulation and function of IKK and IKK-related kinases. Sci STKE 2006(357):re13.
21. Cheng SM, Xing B, Li JC, Cheung BK, Lau AS (2007) Interferon-gamma regulation of TNFalpha-induced matrix metalloproteinase 3 expression and migration of human glioma T98G cells. Int J Cancer 121(6):1190-1196.
22. Shih VF, et al. (2012) Control of RelB during dendritic cell activation integrates canonical and noncanonical NF-κB pathways. Nat Immunol 13(12):1162-1170.
23. Sun SC (2012) The noncanonical NF-κB pathway. Immunol Rev 246(1):125-140.
24. Baud V, Jacque E (2008) [The alternative NF-kB activation pathway and cancer: Friend or foe?] Med Sci (Paris) 24(12):1083-1088.
25. Werner SL, Barken D, Hoffmann A (2005) Stimulus specificity of gene expression programs determined by temporal control of IKK activity. Science 309(5742):1857-1861.
26. Leotoing L, et al. (2011) A20-binding inhibitor of nuclear factor-kappaB (NF-kappaB)- 2 (ABIN-2) is an activator of inhibitor of NF-kappaB (IkappaB) kinase alpha (IKKalpha)- mediated NF-kappaB transcriptional activity. J Biol Chem 286(37):32277-32288.
27. Perkins ND (2006) Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene 25(51):6717-6730.
28. Lawrence T, Bebien M, Liu GY, Nizet V, Karin M (2005) IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 434(7037):1138-1143.
29. Sakurai H, Chiba H, Miyoshi H, Sugita T, Toriumi W (1999) IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J Biol Chem 274(43):30353-30356.
30. Msaki A, et al. (2011) The role of RelA (p65) threonine 505 phosphorylation in the regulation of cell growth, survival, and migration. Mol Biol Cell 22(17):3032-3040.
31. Rocha S, Garrett MD, Campbell KJ, Schumm K, Perkins ND (2005) Regulation of NF-kappaB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. EMBO J 24(6):1157-1169.
32. Busino L, et al. (2012) Fbxw7α- And GSK3-mediated degradation of p100 is a prosurvival mechanism in multiple myeloma. Nat Cell Biol 14(4):375-385.
33. Bonizzi G, et al. (2004) Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO J 23(21):4202-4210.
34. Hailfinger S, et al. (2011) Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines. Proc Natl Acad Sci USA 108(35):14596-14601.
35. Marienfeld R, et al. (2001) Signal-specific and phosphorylation-dependent RelB degradation: A potential mechanism of NF-kappaB control. Oncogene 20(56):8142-8147.
36. Puto LA, Reed JC (2008) Daxx represses RelB target promoters via DNA methyltransferase recruitment and DNA hypermethylation. Genes Dev 22(8):998-1010.
37. Wang X, et al. (2007) Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol 9(4):470-478.
38. Xu Y, et al. (2009) RelB enhances prostate cancer growth: Implications for the role of the nuclear factor-kappaB alternative pathway in tumorigenicity. Cancer Res 69(8):3267-3271.
39. Lee DW, et al. (2013) The NF-κB RelB protein is an oncogenic driver of mesenchymal glioma. PLoS ONE 8(2):e57489.
40. Kessenbrock K, Plaks V, Werb Z (2010) Matrix metal oproteinases: Regulators of the tumor microenvironment. Cell 141(1):52-67.